Skip to main content
SpringerLink
Log in

Orphan nuclear receptors find a home in the arterial wall

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Orphan nuclear receptors of the peroxisome proliferator activated receptor (PPAR) and liver X receptor (LXR) subfamilies have been shown to play critical roles in both local and systemic lipid metabolism. The PPARs control fatty acid metabolism in various cell types, including adipocytes, liver, and macrophages. The LXRs have been implicated in the regulation of cholesterol metabolism in the liver, intestines, and macrophages. The importance of these receptors in physiologic lipid metabolism suggests that they may influence the development of metabolic disorders such as obesity, diabetes, and atherosclerosis. Furthermore, the ability of these receptors to be modulated pharmacologically makes them attractive therapeutic targets. This review focuses on the role of PPAR and LXR signaling pathways in macrophage lipid metabolism and the potential of these pathways to modulate the development of atherosclerosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mangelsdorf DJ, Thummel C, Beato M, et al.: The nuclear receptor superfamily: the second decade. Cell 1995, 83:835–839.

    Article  PubMed  CAS  Google Scholar 

  2. Kliewer SA, Lehmann JM, Willson TM: Orphan nuclear receptors: shifting endocrinology into reverse. Science 1999, 284:757–760.

    Article  PubMed  CAS  Google Scholar 

  3. Repa JJ, Mangelsdorf DJ: The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Ann Rev Cell Dev Biol 2000, 16:459–481.

    Article  CAS  Google Scholar 

  4. Forman BM, Chen J, Evans RM: Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 1997, 94:4312–4317.

    Article  PubMed  CAS  Google Scholar 

  5. Kliewer SA, Sundseth SS, Jones SA, et al.: Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A 1997, 94:4318–4323.

    Article  PubMed  CAS  Google Scholar 

  6. Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM: Transcriptional regulation of adipogenesis. Genes Dev 2000, 14:1293–1307.

    PubMed  CAS  Google Scholar 

  7. Forman BM, Tontonoz P, Chen J, et al.: 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995, 83:803–812.

    Article  PubMed  CAS  Google Scholar 

  8. Lehmann JM, Moore LB, Smith-Oliver TA, et al.: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995, 270:12953–12956.

    Article  PubMed  CAS  Google Scholar 

  9. Leibowitz MD, Fievet C, Hennuyer N, et al.: Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett 2000, 473:333–336.

    Article  PubMed  CAS  Google Scholar 

  10. Oliver WR Jr, Shenk JL, Snaith MR, et al.: A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A 2001, 98:5306–5311.

    Article  PubMed  CAS  Google Scholar 

  11. Fu X, Menke JG, Chen Y, et al.: 27-Hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem 2001, 276:38378–38387.

    Article  PubMed  CAS  Google Scholar 

  12. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ: An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996, 383:728–731.

    Article  PubMed  CAS  Google Scholar 

  13. Lehmann JM, Kliewer SA, Moore LB, et al.: Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem 1997, 272:3137–3140.

    Article  PubMed  CAS  Google Scholar 

  14. Laffitte BA, Joseph SB, Walczak R, et al.: Autoregulation of the human liver X receptor alpha promoter. Mol Cell Biol 2001, 21:7558–7568.

    Article  PubMed  CAS  Google Scholar 

  15. Schultz JR, Tu H, Luk A, et al.: Role of LXRs in control of lipogenesis. Gene Dev 2000, 14:2831–2838.

    Article  PubMed  CAS  Google Scholar 

  16. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrinol Rev 1999, 20:649–688.

    Article  CAS  Google Scholar 

  17. Glass CK, Witztum JL: Atherosclerosis. the road ahead. Cell 2001, 104:503–516.

    Article  PubMed  CAS  Google Scholar 

  18. Lusis AJ: Atherosclerosis. Nature 2000, 407:233–241.

    Article  PubMed  CAS  Google Scholar 

  19. Lee H, Shi W, Tontonoz P, et al.: Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ Res 2000, 87:516–521.

    PubMed  CAS  Google Scholar 

  20. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J: PPAR alpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999, 99:3125–3131.

    PubMed  CAS  Google Scholar 

  21. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM: Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998, 93:229–240.

    Article  PubMed  CAS  Google Scholar 

  22. Ricote M, Huang J, Fajas L, et al.: Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1998, 95:7614–7619.

    Article  PubMed  CAS  Google Scholar 

  23. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM: PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998, 93:241–252.

    Article  PubMed  CAS  Google Scholar 

  24. Law RE, Meehan WP, Xi XP, et al.: Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996, 98:1897–1905.

    PubMed  CAS  Google Scholar 

  25. Huang JT, Welch JS, Ricote M, et al.: Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 1999, 400:378–382.

    Article  PubMed  CAS  Google Scholar 

  26. Laffitte BA, Repa JJ, Joseph SB, et al.: LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci U S A 2001, 98:507–512.

    Article  PubMed  CAS  Google Scholar 

  27. Venkateswaran A, Repa JJ, Lobaccaro JM, et al.: Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages. A transcriptional role for specific oxysterols. J Biol Chem 2000, 275:14700–14707.

    Article  PubMed  CAS  Google Scholar 

  28. Xu HE, Lambert MH, Montana VG, et al.: Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 1999, 3:397–403.

    Article  PubMed  CAS  Google Scholar 

  29. Chawla A, Barak Y, Nagy L, et al.: PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001, 7:48–52.

    Article  PubMed  CAS  Google Scholar 

  30. Moore KJ, Rosen ED, Fitzgerald ML, et al.: The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med 2001, 7:41–47.

    Article  PubMed  CAS  Google Scholar 

  31. Chinetti G, Gbaguidi FG, Griglio S, et al.: CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000, 101:2411–2417.

    PubMed  CAS  Google Scholar 

  32. Hayden MR, Clee SM, Brooks-Wilson A, et al.: Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency. Curr Opin Lipidol 2000, 11:117–122.

    Article  PubMed  CAS  Google Scholar 

  33. Claudel T, Leibowitz MD, Fievet C, et al.: Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc Natl Acad Sci U S A 2001, 98:2610–2615.

    Article  PubMed  CAS  Google Scholar 

  34. Repa JJ, Turley SD, Lobaccaro JA, et al.: Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000, 289:1524–1529.

    Article  PubMed  CAS  Google Scholar 

  35. Venkateswaran A, Laffitte BA, Joseph SB, et al.: Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci U S A 2000, 97:12097–12102.

    Article  PubMed  CAS  Google Scholar 

  36. Costet P, Luo Y, Wang N, Tall AR: Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem 2000, 275:28240–28245.

    PubMed  CAS  Google Scholar 

  37. Chawla A, Boisvert WA, Lee CH, et al.: A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001, 7:161–171.

    Article  PubMed  CAS  Google Scholar 

  38. Chinetti G, Lestavel S, Bocher V, et al.: PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001, 7:53–58.

    Article  PubMed  CAS  Google Scholar 

  39. Jiang C, Ting AT, Seed B: PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82–86.

    Article  PubMed  CAS  Google Scholar 

  40. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK: The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79–82.

    Article  PubMed  CAS  Google Scholar 

  41. Thieringer R, Fenyk-Melody JE, Le Grand CB, et al.: Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo. J Immunol 2000, 164:1046–1054.

    PubMed  CAS  Google Scholar 

  42. Rossi A, Kapahi P, Natoli G, et al.: Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 2000, 403:103–108.

    Article  PubMed  CAS  Google Scholar 

  43. Straus DS, Pascual G, Li M, et al.: 15-deoxy-delta 12, 14-prostaglandin J2 inhibits multiple steps in the NF- kappa B signaling pathway. Proc Natl Acad Sci U S A 2000, 97:4844–4849.

    Article  PubMed  CAS  Google Scholar 

  44. Han KH, Chang MK, Boullier A, et al.: Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma. J Clin Invest 2000, 106:793–802.

    PubMed  CAS  Google Scholar 

  45. Kintscher U, Goetze S, Wakino S, et al.: Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur J Pharmacol 2000, 401:259–270.

    Article  PubMed  CAS  Google Scholar 

  46. Pasceri V, Wu HD, Willerson JT, Yeh ET: Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000, 101:235–238.

    PubMed  CAS  Google Scholar 

  47. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J: Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998, 153:17–23.

    PubMed  CAS  Google Scholar 

  48. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J: Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998, 83:1097–1103.

    PubMed  CAS  Google Scholar 

  49. Collins AR, Meehan WP, Kintscher U, et al.: Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001, 21:365–371.

    PubMed  CAS  Google Scholar 

  50. Li AC, Brown KK, Silvestre MJ, et al.: Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000, 106:523–531.

    PubMed  CAS  Google Scholar 

  51. Chen Z, Ishibashi S, Perrey S, et al.: Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 2001, 21:372–377.

    PubMed  CAS  Google Scholar 

  52. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H: Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998, 83:1818–1820.

    Article  PubMed  CAS  Google Scholar 

  53. Ericsson CG, Nilsson J, Grip L, Svane B, Hamsten A: Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]). Am J Cardiol 1997, 80:1125–1129.

    Article  PubMed  CAS  Google Scholar 

  54. Frick MH, Syvanne M, Nieminen MS, et al.: Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997, 96:2137–2143.

    PubMed  CAS  Google Scholar 

  55. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410–418.

    Article  PubMed  CAS  Google Scholar 

  56. Tordjman K, Bernal-Mizrachi C, Zemany L, et al.: PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J Clin Invest 2001, 107:1025–1034.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Howard Hughes Medical Institute, UCLA School of Medicine, Box 951662, 90095-1662, Los Angeles, CA, USA

    Bryan A. Laffitte PhD & Peter Tontonoz MD, PhD

Authors
  1. Bryan A. Laffitte PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Tontonoz MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Laffitte, B.A., Tontonoz, P. Orphan nuclear receptors find a home in the arterial wall. Curr Atheroscler Rep 4, 213–221 (2002). https://doi.org/10.1007/s11883-002-0022-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-002-0022-6

Keywords

Search

Navigation